Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CHICAGO, Ill. , July 2, 2015  AbbVie ... financial results on Friday, July 24, 2015, before the ... webcast of the earnings conference call at 8 a.m. ... through AbbVie,s Investor Relations website at www.abbvieinvestor.com . ... after 11 a.m. Central time. About AbbVie ...
(Date:7/2/2015)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... and tissue hypothermic storage and cryopreservation freeze ... chain management app for smart shippers ("BioLife" ... has included BioLife in its annual list of the ... state for 2015. Now in its ...
(Date:7/2/2015)... July 2, 2015 BGI announced today that ... Kong has been accredited by the American ... the first clinical next-generation-sequencing laboratory to receive the CAP ... highest standard in clinical laboratory practices. Complementary to the exiting ... process, and multiple ISO certifications, the CAP certification enables ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3BGI Receives Accreditation from the College of American Pathologists (CAP) 2
... Up to Four Years of Treatment Presented at ... Schering-Plough,Corporation (NYSE: SGP ) today reported a ... antagonist, demonstrated,sustained viral suppression and increased CD4 cell ... years of therapy in treatment-experienced,HIV-infected patients. Vicriviroc was ...
... Phase III studies affirmed the clinical benefits of,ACTEMRA ... from two Phase III studies,showed that patients who ... arthritis (RA) achieved significant improvements in signs and,symptoms ... combination,with methotrexate compared with methotrexate alone. The final ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:7/3/2015)... ... 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce the ... Center website. Just as the previous version did, the new website will serve as ... and ovarian cancer warning information. The site is routinely updated with news articles on ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Every year, ... 24-Hour Train-a-Thon where they provide members of the Red Deer community with free fitness ... day of fitness training, games, food, events and entertainment raised thousands of charity dollars ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Following the recent ... the number of obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a ... threats to American society right now," Becic said. "We must understand the magnitude of ...
(Date:7/2/2015)... Bolingbrook, IL (PRWEB) , ... July 02, 2015 , ... In 2012, Patrick Achebe realized ... when he was alone. He sat down to write his first poem, and three years ... of him that was special and worth sharing with the world. "I have always believed ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his 80th birthday, Don ... awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk ... Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making his ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... speakers from across the United States and abroad ... and Responsibility for the 21st Century, an interdisciplinary ... University of Delaware,s Clayton Hall Conference Center in ... business, the ethical basis of carbon trading, responsible ...
... by father,s concern for son with debilitating condition , , THURSDAY, ... son led to research that now sheds new light on ... Andrew Chia, now 24, was diagnosed with debilitating chronic fatigue ... his father, Dr. John Chia, of a study which links ...
... of Maine now offers a complete, natural, effective, ... and now floss , KENNEBUNK, Maine, Sept. ... personal care products and values-based business, reaffirms its,commitment ... its natural,antiplaque dental floss has earned the American ...
... Nationwide Effort Encourages Parents to Pack Assorted Colors ... As part of the new Fruits &,Veggies-More Matters(TM) ... fruits and vegetables in their diets,September has become ... call-to- action, Welch,s has declared September 24-28, 2007,P.A.C.K. ...
... Efficiency in Medical Device Manufacturing, explores industry ... operational excellence, ATLANTA, Sept. 13 Visiprise, ... the integrated enterprise,announced today that the company will ... in the medical device industry. Titled "Operational,Efficiency in ...
... Caribbean Hospital Becomes Latest SafeTrace Tx(R) User, ... Bulletin Board: GLOB) today announced that its Wyndgate,Technologies(R) ... to the,Cardiovascular Center of Puerto Rico and the ... the agreement were not disclosed. (Logo: ...
Cached Medicine News:Health News:Environment, Energy and Ethics conference at UD, Sept. 21-23 2Health News:Stomach Virus a Culprit in Chronic Fatigue Syndrome 2Health News:Stomach Virus a Culprit in Chronic Fatigue Syndrome 3Health News:Tom's of Maine Tooth Floss Earns American Dental Association's Seal of Acceptance 2Health News:P.A.C.K. Week Declared in Support of Fruits & Veggies-More Matters Month 2Health News:P.A.C.K. Week Declared in Support of Fruits & Veggies-More Matters Month 3Health News:Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers 2Health News:Global Med Technologies(R) Extends Its Worldwide Outreach 2Health News:Global Med Technologies(R) Extends Its Worldwide Outreach 3
... new OTI-Scan 1000 is the most advanced ... B/A-scan system operates with a single Macintosh ... B-scans with a streamlined internal probe rotator. ... newly designed. The UltraFast 12 MHz B-probe ...
... The B5500 is a sensitive B-scan system ... the axial length of both eyes differ by ... ocular abnormality must be suspected. The B5500 enables ... setting up a water bath or inserting shells ...
... A-scan and B-scan system, providing accurate and ... high frequency, low noise probe and fast ... upon application of the probe along the ... length of both eyes differ by more ...
... The CineScan A/B represent a true breakthrough ... image with technology and diagnostic capability previously ... the vitreous. Adjust the gain up to ... be invisible at a standard 90db setting ...
Medicine Products: